Mycosis Fungoides as a Multifaceted Disease – A Case Report
DOI:
https://doi.org/10.26332/dvtrqf94Keywords:
epidermotropism, methotrexate, Mycosis fungoidesAbstract
Abstract
Introduction: Mycosis fungoides (MF) is a primary cutaneous T-cell lymphoma with a highly variable clinical presentation, while histological findings are often typical. This case report presents an atypical, mimicking manifestation of MF in a 66-year-old patient, whose diagnosis required a multidisciplinary approach.
Case presentation: The patient was hospitalized twice at the Department of Dermatology and venerology, University Hospital Centre Osijek, due to a persistent polymorphic rash of changing appearance, localized on the trunk, extremities, face, and the scalp. Considering the atypical clinical course, resistance to topical and systemic therapy, further diagnostic evaluation was required, including immunological, hematological, pulmonary, and infectious disease workup. Multidisciplinary collaboration ultimately led to the establishment of the MF diagnosis.
Management and outcome: After failing to respond to topical and systemic corticosteroids, immunomodulators, antibiotics, and hydroxychloroquine, the patient showed a successful therapeutic response to oral methotrexate at a dose of 15 mg once weekly, resulting in complete resolution of skin lesions.
Discussion: This clinical case serves as an example of an atypical clinical and histological presentation of MF, along with associated multiple pathological findings, which necessitated the exclusion of several other differential diagnoses.
Conclusion: MF can mimic a wide spectrum of benign inflammatory dermatoses, both clinically and histopathologically. Confirming the diagnosis of MF, the so-called “great imitaror”, requires a multidisciplinary approach to both diagnosis and patient management.
Keywords: epidermotropism; methotrexate; Mycosis fungoides
References
1. Basta-Juzbašić A. Dermatovenerologija. Zagreb: Medicinska naklada; 2014. 826 p.
2. Yamashita T, Abbade LPF, Marques MEA, Marques SA. Mycosis fungoides and Sézary syndrome: clinical, histopathological and immunohistochemical review and update. An Bras Dermatol. 2012 Dec;87(6):817–30.
3. Hristov AC, Tejasvi T, Wilcox RA. Mycosis fungoides and Sézary syndrome: 2019 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2019 Sept;94(9):1027–41.
4. Hristov AC, Tejasvi T, A. Wilcox R. Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2021 Oct;96(10):1313–28.
5. Hristov AC, Tejasvi T, Wilcox RA. Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management. Am J Hematol. 2023 Jan;98(1):193–209.
6. Larocca C, Kupper T. Mycosis Fungoides and Sézary Syndrome. Hematol Oncol Clin North Am. 2019 Feb;33(1):103–20.
7. Maguire A, Puelles J, Raboisson P, Chavda R, Gabriel S, Thornton S. Early-stage Mycosis Fungoides: Epidemiology and Prognosis. Acta Derm Venereol. 2020;100(1):1–6.
8. Sheern C, Levell NJ, Craig PJ, Jeffrey P, Mistry K, Scorer MJ, et al. Mycosis fungoides: a review.
9. Miyashiro D, Sanches JA. Mycosis fungoides and Sézary syndrome: clinical presentation, diagnosis, staging, and therapeutic management. Front Oncol. 2023 Apr 14;13:1141108.
10. Mathur M, Thakur N, Regmi S, Paudel S, Karki S, Bhattarai N. “Missed” Diagnosis of Mycosis Fungoides: A Case Report. Clin Case Rep. 2025 Feb;13(2):e70172.
11. Spaccarelli N, Rook AH. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma. Dermatol Clin. 2015 Oct;33(4):731–45.
12. Latzka J, Assaf C, Bagot M, Cozzio A, Dummer R, Guenova E, et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2023. Eur J Cancer. 2023 Dec;195:113343.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Žgela M, Lukenda L, Vukšić Polić M.

This work is licensed under a Creative Commons Attribution 4.0 International License.